



(11) **EP 1 350 262 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 15/11 (2006.01) A61K 31/70 (2006.01)

(48) Corrigendum issued on:
13.08.2008 Bulletin 2008/33

(86) International application number:
PCT/IB2001/002888

(45) Date of publication and mention
of the grant of the patent:
11.06.2008 Bulletin 2008/24

(87) International publication number:
WO 2002/069369 (06.09.2002 Gazette 2002/36)

(21) Application number: **01273824.1**

(22) Date of filing: **10.12.2001**

(54) **CPG-LIKE NUCLEIC ACIDS AND METHODS OF USE THEREOF**

CPG-ARTIGE NUKLEINSÄUREN UND VERFAHREN ZU IHRER VERWENDUNG

ACIDES NUCLEIQUES DU TYPE CPG ET PROCEDES D'UTILISATION CORRESPONDANTS

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **08.12.2000 US 254341 P**

(43) Date of publication of application:
08.10.2003 Bulletin 2003/41

(60) Divisional application:
08157972.4

(73) Proprietor: **Coley Pharmaceutical GmbH
40225 Düsseldorf (DE)**

(72) Inventors:
• **SCHETTER, Christian
40723 Hilden (DE)**
• **VOLLMER, Jörg
40591 Düsseldorf (DE)**

(74) Representative: **Jump, Timothy John Simon et al
Venner Shipley LLP
20 Little Britain
London EC1A 7DH (GB)**

(56) References cited:
WO-A-01/93903

- **GOECKERITZ B.E. ET AL.: "Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion" INTERNATIONAL IMMUNOLOGY, vol. 11, no. 10, 1999, pages 1693-1700, XP000938323**
- **BOGGS R.T. ET AL.: "Characterization and modulation of immune stimulation by modified oligonucleotides" ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 7, 1 October 1997 (1997-10-01), pages 461-471, XP002053418 ISSN: 1087-2906**
- **YAMAMOTO T. ET AL.: "Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AAGCTT to murine splenocytes enhances Interferon production and natural killer activity" MICROBIOLOGY AND IMMUNOLOGY, vol. 38, no. 10, 1994, pages 831-836, XP008012406**
- **HENRY S. ET AL.: "Chemically modified olioligonucleotides exhibit decreased immune stimulation in mice" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 292, no. 2, February 2000 (2000-02), pages 468-479, XP002310045**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 350 262 B8

- | | |
|--|---|
| <ul style="list-style-type: none"> • ZHAO Q. ET AL.: "Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 10, May 2000 (2000-05), pages 1051-1054, XP004204603 ISSN: 0960-894X • KRIEG A.M.: "Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides" BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1489, no. 1, 10 December 1999 (1999-12-10), pages 107-116, XP004275526 ISSN: 0167-4781 | <ul style="list-style-type: none"> • BAILLY C. ET AL.: "Recognition elements that determine affinity and sequence-specific binding to DNA of 2QN, a biosynthetic bis-quinoline analogue of echinomycin" ANTI-CANCER DRUG DESIGN, vol. 14, 1999, pages 291-303, XP008040033 |
|--|---|